ESMO Consensus Guidelines: Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy

Published in 2011 - Ann Oncol (2011) 22 (7): 1507-1519.
Authors: E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel

The consensus agreement on these areas: NSCLC pathology and molecular testing, the treatment of first-line, and second-line/third-line therapy in metastatic NSCLC are reported in this article.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings